ArticleCancer discovery2011
Characterization of KRAS rearrangements in metastatic prostate cancer.
Article in Cancer discovery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 103 citations in OpenAlex.
- Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities.British journal of cancer · 2026Review
- Fibroblast-mediated KRAS activation in double-negative prostate cancer.Cell death & disease · 2026Article
- Pleomorphic Giant Cell Carcinoma of the Prostate Treated With Lutetium-177 PSMA.Case reports in urology · 2026Article
- Mechanistic insights and molecular therapy for neuroendocrine prostate cancer.Frontiers in oncology · 2026Review
- Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Signal transduction and targeted therapy · 2025Review
- Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Network Pharmacology and Molecular Dynamics Identified Potential Androgen Receptor-Targeted Metabolites inInternational journal of molecular sciences · 2025Article
- Systematic Analysis of E3 Ligase-Related Genes Identified UBE2L3 as a Prognostic Biomarker Associated With Drug Resistance in Acute Myeloid Leukemia.International journal of general medicine · 2025Article
- Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.Molecular cancer research : MCR · 2024Article
- Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review.Cancers · 2024Review
- Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review.BMC medical genomics · 2022Review
- Mechanism and Disease Association With a Ubiquitin Conjugating E2 Enzyme: UBE2L3.Frontiers in immunology · 2022Review
- Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells.Frontiers in oncology · 2022Article
- The impact of fusion genes on cancer stem cells and drug resistance.Molecular and cellular biochemistry · 2021Review
- TargetingCancers · 2021Review
- Downregulation of PARVA promotes metastasis by modulating integrin-linked kinase activity and regulating MAPK/ERK and MLC2 signaling in prostate cancer.Translational andrology and urology · 2021Article
- Synthesis of the PET TracerJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- HPV-mediated nuclear export of HP1γ drives cervical tumorigenesis by downregulation of p53.Cell death and differentiation · 2020Article
- Pathway Analysis of Genes Identified through Post-GWAS to Underpin Prostate Cancer Aetiology.Genes · 2020Article
- Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
26 authors at 6 institutions in 1 country.
Funding
Abstract
unlabelledUsing an integrative genomics approach called amplification breakpoint ranking and assembly analysis, we nominated KRAS as a gene fusion with the ubiquitin-conjugating enzyme UBE2L3 in the DU145 cell line, originally derived from prostate cancer metastasis to the brain. Interestingly, analysis of tissues revealed that 2 of 62 metastatic prostate cancers harbored aberrations at the KRAS locus. In DU145 cells, UBE2L3-KRAS produces a fusion protein, a specific knockdown of which attenuates cell invasion and xenograft growth. Ectopic expression of the UBE2L3-KRAS fusion protein exhibits transforming activity in NIH 3T3 fibroblasts and RWPE prostate epithelial cells in vitro and in vivo. In NIH 3T3 cells, UBE2L3-KRAS attenuates MEK/ERK signaling, commonly engaged by oncogenic mutant KRAS, and instead signals via AKT and p38 mitogen-activated protein kinase (MAPK) pathways. This is the first report of a gene fusion involving the Ras family, suggesting that this aberration may drive metastatic progression in a rare subset of prostate cancers. SIGNIFICANCE: This is the first description of an oncogenic gene fusion of KRAS, one of the most studied proto-oncogenes. KRAS rearrangement may represent the driving mutation in a rare subset of metastatic prostate cancers, emphasizing the importance of RAS-RAF-MAPK signaling in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.